ADC THERAPEUTICS SA reports a Return on Equity (ROE) of 63.31%.

What is ADCT's dividend yield?

ADC THERAPEUTICS SA offers a dividend yield of 0.00%.

What is ADCT's Quality Score?

Our AI rates ADCT's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ADCT?

Our AI Timing Score for ADCT is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ADCT belong to?

ADC THERAPEUTICS SA is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NYSE exchange

ADCT (NYSE) Stock Analysis | ADC THERAPEUTICS SA

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

ADCT AI Analysis Summary

Our AI summary for ADCT: ADC THERAPEUTICS SA (NYSE), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 0.00, ROE of 63.31%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ADCT

ADC THERAPEUTICS SA

US:NYSE STOCK Healthcare >> Drug Manufacturers - Specialty & Generic

USD 1.05

-0.06 (-5.41%) Day Change

Watchlist Portfolio Compare Chart

-0.53

D/E

63.3%

ROE

-47.0%

ROA

0.00%

Div Yield

ADC THERAPEUTICS SA
TYPE: STOCK
MARKET: NYSE

Compare Watchlist Myport

USD 1.05 Price -0.06 (-5.41%) Day Change	NEWS SCORE: N/A

ADCT, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...

Loading chart...

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.05
PBV / Sector	-0.65 / 3.22
Earning Per Share	-1.02

PE / Sector	N/A / 29.79
PEG or PE/Growth / Sector	N/A / 0.13
Average 1M Daily Value	1.26 M GREAT
Average 1W Daily Value	0.90 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-173.02 / 15.21
NPM Average (%) / Sector	-198.22 / -10.83
NPM Change Average (%) / Sector	75.74 / 117.42 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-47.00 / 8.15
ROA Average (%) / Sector	-47.97 / 2.87
ROA Change Average (%) / Sector	20.08 / 112.70 GREAT
ROE (%) / Sector	63.31 / -1.02 GREAT
ROE Average (%) / Sector	36.42 / 8.35 GREAT
ROE Change Average (%) / Sector	-63.19 / 385.91
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Registration Details

Analyze Date	2026-08-01 07:59:26
Symbol	ADCT
Name	ADC THERAPEUTICS SA
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NYSE
Listed Shares	127.19 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	141.18 / 10,754.62

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: BiopOle, Epalinges, Switzerland, 1066

Phone: 41 21 653 02 00

Website: https://www.adctherapeutics.com

Employees: 188

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.